Telix FY2020 Results and Company Update Conference Call
Telix to present the Company’s FY2020 results together with an update on Telix’s operations.
Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
Telix announces the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorization allowing the use of TLX591-CDx
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Telix announces research cooperation agreement with Heidelberg University Hospital to develop next-generation theranostic radiopharmaceuticals for urologic oncology.
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Telix has filed a New Drug Submission (NDS) with Health Canada for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton, UK
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography (PET).
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with DuChemBio
Investor Briefing – TheraPharm GmbH Acquisition
Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition.
Investor Conference Call: Telix’s acquisition of TheraPharm GmbH
Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm GmbH.
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH
Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.